证券代码：301103 证券简称：何氏眼科 公告编号：2025-025 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）第三届董事会第 十一次会议于 2025 年 8 月 26 日在公司会议室以现场及通讯相结合的方式召开。 会议通知于 2025 年 8 月 16 日以邮件、电话等方式送达全体董事。会议由董事长 何伟先生主持，应出席董事 7 名，实际出席董事 7 名。公司监事及高级管理人员 列席了会议。本次会议的召集和召开符合《中华人民共和国公司法》等法律、法 规、规范性文件和《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 经与会董事审议，作出如下决议： （一）审议通过《关于<2025 年半年度报告>及其摘要的议案》 公司董事会在全面审核公司 2025 年半年度报告及摘要后，一致认为：公司 编制《公司 2025 年半年度报告全文及其摘要》的程序符合法律、行政法规和中 国证券监督管理委员会的有关规定，报告内容公允地反映了公司 2025 年半年度 的经营状况和经营成果，报告所披露的信息真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 辽宁何氏眼科医院集团股份有限公司 第三届董事会第十一 ...

中原证券股份有限公司 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 不适用 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防 | | | 止关联方占用公司资源的制度、募集资金管理制度、内 | 是 | | 控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 1 次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 未亲自列席，已阅会议 | | | 文件 | | （2）列席公司董事会次数 | 未亲自列席，已阅会议 | | | 文件 | | （3）列席公司监事会次数 | 未亲自列席，已阅会议 | | | 文件 | | 5.现场检查情况 | | | （1）现场检查次数 | 1 次 ...

中原证券股份有限公司关于 辽宁何氏眼科医院集团股份有限公司 使用部分超募资金注资全资子公司收购 日本株式会社医道メディカル 70.65%股权的核查意见 中原证券股份有限公司（以下简称"中原证券"或"保荐机构"）作为辽宁何氏 眼科医院集团股份有限公司（以下简称"何氏眼科"、"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关规定，对何氏眼科使用部分超募资金注资全资子公司收 购日本株式会社医道メディカル 70.65%股权的情况进行了审慎核查。核查情况 及核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意辽宁何氏眼科医院集团股份有限公司 首次公开发行股票注册的批复》（证监许可【2022】126 号）同意注册，公司首 次公开发行人民币普通股（A 股）3,050.00 万股，每股面值 1 元，每股发行价格 为人民币 42.50 元，募集资金总额为人民币 129,625.00 万元， ...

2025 年半年度报告 2025-023 2025 年 8 月 1 辽宁何氏眼科医院集团股份有限公司 2025 年半年度报告全文 辽宁何氏眼科医院集团股份有限公司 辽宁何氏眼科医院集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人何伟、主管会计工作负责人何跃华及会计机构负责人(会计主 管人员)王艳明声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预 测与承诺之间的差异。 公司在本报告"第三节 管理层讨论与分析"中"十、公司面临的风险和应对 措施"部分描述了公司经营中可能面临的风险及应对措施，敬请投资者注意并 仔细阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | 以上备查文件的备置地点：公司证券业 ...

（文章来源：证券日报） 证券日报网讯 8月25日晚间，何氏眼科发布公告称，公司于2025年4月23日召开第三届董事会第十次会 议，并于2025年5月22日召开2024年年度股东大会，审议通过了《关于增加经营范围、修订并办理工商 变更登记的议案》。近日，公司完成了工商变更登记手续，并取得了沈阳市市场监督管理局换发的营业 执照。 ...

Core Insights - A research team from Liaoning He University and Shenyang He Eye Hospital published a study in the international journal "BMJ OPEN OPHTHALMOLOGY" comparing the vision-related quality of life and clinical efficacy of orthokeratology lenses (OK lenses), defocus glasses (DS glasses), and single vision glasses (SVS glasses) for myopic children and adolescents, providing important references for clinical choices in myopia optical interventions [1] Group 1 - The He Eye Hospital has actively responded to the national initiative "Light Project" by collaborating with Liaoning He University and He Eye Industry Group to establish a "365 Myopia Prevention and Control System" that utilizes big data, artificial intelligence, and genetic technologies [1] - This system emphasizes "precision" as a primary principle, customizing personalized plans based on genetic testing and vision examination data, addressing the shortcomings of traditional models [1] - The system covers the entire myopia development cycle, including prevention, early warning, control, and intervention, providing continuous management services [1] Group 2 - The integration of artificial intelligence and genetic diagnosis technologies allows for scientific risk prediction through myopia gene testing, enabling targeted measures to be taken [1] - The trend of early onset myopia is concerning, as high myopia, if not intervened in a timely manner, may lead to severe eye diseases such as retinal detachment [1] - Currently, SVS glasses are widely used due to their safety and affordability, while OK lenses and DS glasses are gradually gaining attention as new methods [1] Group 3 - The research team acknowledged limitations in their study and indicated the need for further research on the differences between various brands of lenses to provide more precise evidence for personalized correction plans [2]

证券代码：301103 证券简称：何氏眼科 公告编号：2025-022 辽宁何氏眼科医院集团股份有限公司 关于完成工商变更登记并取得换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次变更的审批程序 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第三届董事会第十次会议，并于 2025 年 5 月 22 日召开 2024 年年度股东 大会，审议通过了《关于增加经营范围、修订<公司章程>并办理工商变更登记 的议案》。具体内容详见公司于 2025 年 4 月 25 日在巨潮资讯网披露的《关于增 加经营范围、修订<公司章程>并办理工商变更登记的公告》（公告编号：2025-012）。 二、新取得营业执照的基本信息 公司于近日完成了工商变更登记手续，并取得了沈阳市市场监督管理局换发 的营业执照。新营业执照基本信息如下： 企业名称：辽宁何氏眼科医院集团股份有限公司 统一社会信用代码： 法定代表人：何伟 类型：股份有限公司 注册资本：人民币壹亿伍仟捌佰零贰万陆仟肆佰柒拾壹元整 住所：辽宁省沈阳市浑南区天赐街 ...

Core Viewpoint - The research published in the international ophthalmology journal "BMJ OPEN OPHTHALMOLOGY" evaluates and compares the vision-related quality of life and clinical efficacy of different optical interventions for myopic children and adolescents in China, providing important references for clinical choices in myopia optical intervention [1] Group 1: Industry Context - The prevalence of myopia among children and adolescents in China is increasing, characterized by younger onset and more severe cases, which has raised significant social concerns [1] - The company actively responds to the national initiative "Light Project" by collaborating with various institutions to address myopia prevention and control [1] Group 2: Technological Integration - The establishment of the "365 Myopia Prevention and Control System" incorporates new technologies such as big data, artificial intelligence, and genetics to create personalized intervention plans based on genetic testing and vision examination data [1] - The system covers the entire myopia development cycle, including prevention, early warning, control, and intervention, providing continuous management services [1]

Core Insights - The research published in the international ophthalmology journal "BMJ OPEN OPHTHALMOLOGY" evaluates and compares the effectiveness and quality of life related to vision for children and adolescents wearing orthokeratology lenses (OK lenses), defocus glasses (DS glasses), and single vision glasses (SVS glasses) in China [1][2][3] Group 1: Research Findings - The study involved a cohort of 93 myopic children aged 7 to 17, divided into three groups wearing OK lenses, DS glasses, and SVS glasses, with a follow-up period of one year [1] - The results indicated significant differences in axial length growth among the three groups: the OK lens group showed an increase of only 0.18±0.08 mm, while the DS lens group had 0.27±0.08 mm, and the SVS lens group had 0.36±0.09 mm [2] - The OK lenses were found to control axial growth approximately 33% better than DS glasses and 50% better than SVS glasses, highlighting the advantages of newer lens types in preventing myopia progression [2] Group 2: Quality of Life Assessment - The study assessed quality of life using the internationally recognized "Children's Refractive Error Quality of Life Questionnaire" (PREP), which covers various dimensions such as distance vision, activity ability, and peer evaluation [1] - OK lenses demonstrated superior performance in multiple quality of life indicators, attributed to factors such as not needing to wear glasses during the day, unrestricted movement, reduced appearance anxiety, and clearer vision [2] - However, OK lenses had lower comfort scores compared to single vision glasses and required more complex maintenance, while DS glasses had lower scores in "near vision" due to their optical design [2] Group 3: Practical Implications - The research provides comprehensive insights for parents and doctors, indicating that while OK lenses have overall better performance, they may not be suitable for all children due to the need for strict screening of eye health and potential infection risks from improper maintenance [3] - DS glasses and SVS glasses are suggested to be more appropriate for children in conditions with limited hygiene or those unable to comply with nighttime lens wear [3]

Core Viewpoint - He Eye Hospital's stock price reached 23.78 yuan as of August 18, 2025, reflecting a 1.28% increase from the previous trading day [1] Company Summary - He Eye Hospital operates in the medical services sector, focusing on ophthalmology, optometry services, and eye health management [1] - The stock opened at 23.60 yuan, peaked at 23.96 yuan, and dipped to a low of 23.49 yuan on the same day [1] - The trading volume was 24,947 hands, with a total transaction value of 0.59 billion yuan [1] Financial Flow Summary - On August 18, the net outflow of main funds was 35.69 thousand yuan, accounting for 0.02% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 713.40 thousand yuan, representing 0.36% of the circulating market value [1]